L
Luis M. Montuenga
Researcher at University of Navarra
Publications - 245
Citations - 10844
Luis M. Montuenga is an academic researcher from University of Navarra. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 48, co-authored 221 publications receiving 9205 citations. Previous affiliations of Luis M. Montuenga include Chartered Institute of Management Accountants & Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours
Silvestre Vicent,José María López-Picazo,Gemma Toledo,Maria D. Lozano,W. Torre,C Garcia-Corchón,C Quero,J-C. Soria,Salvador Martín-Algarra,R G Manzano,Luis M. Montuenga +10 more
TL;DR: It is indicated that nuclear and cytoplasmic ERK1/2 activation positively correlates with stage, T and lymph node metastases, and thus, is associated with advanced and aggressive NSCLC tumours.
Journal ArticleDOI
Early Lung Cancer Detection Using Spiral Computed Tomography and Positron Emission Tomography
Gorka Bastarrika,María José García-Velloso,Maria D. Lozano,Usua Montes,W. Torre,Natalia Spiteri,Arantza Campo,Luis M. Seijo,Ana B. Alcaide,Jesus Pueyo,David A. Cano,Isabel Vivas,Octavio Cosín,Pablo Dominguez,Patricia Serra,José A. Richter,Luis M. Montuenga,Javier J. Zulueta +17 more
TL;DR: A protocol for early lung cancer detection using spiral CT and FDG-PET is useful and may minimize unnecessary invasive procedures for benign lesions.
Journal ArticleDOI
Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer
Irene Pino,Ruben Pio,Gemma Toledo,Natalia Zabalegui,Silvestre Vicent,Natalia Rey,Maria D. Lozano,W. Torre,Jesús García-Foncillas,Luis M. Montuenga +9 more
TL;DR: The results suggest that the expression and processing of each hnRNP protein in lung cancer is independently regulated and is not exclusively related to proliferation status.
Journal ArticleDOI
MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.
Octavio A. Romero,Manuel Torres-Diz,Eva Pros,Suvi Savola,Antonio Gomez,Sebastian Moran,Carmen Sáez,Reika Iwakawa,Alberto Villanueva,Luis M. Montuenga,Takashi Kohno,Jun Yokota,Montse Sanchez-Cespedes +12 more
TL;DR: The discovery of tumor-specific inactivation of the MYC-associated factor X gene, MAX, in SCLC is reported, providing evidence that an aberrant SWI/SNF-MYC network is essential for lung cancer development.
Journal ArticleDOI
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.
Michael Duruisseaux,Anna Martínez-Cardús,Maria E. Calleja-Cervantes,Sebastian Moran,Manuel Castro de Moura,Veronica Davalos,David Piñeyro,Montse Sanchez-Cespedes,Nicolas Girard,Marie Brevet,Etienne Giroux-Leprieur,Coraline Dumenil,Monica Pradotto,Paolo Bironzo,Enrica Capelletto,Silvia Novello,Alexis B. Cortot,Marie-Christine Copin,Niki Karachaliou,Maria Gonzalez-Cao,Sergio Peralta,Luis M. Montuenga,Ignacio Gil-Bazo,Iosune Baraibar,Maria D. Lozano,Mar Varela,Jose Carlos Ruffinelli,Ramon Palmero,Ernest Nadal,Teresa Moran,Lidia Perez,Immaculada Ramos,Qingyang Xiao,Agustín F. Fernández,Mario F. Fraga,Marta Gut,Ivo Gut,Cristina Teixidó,Noelia Vilariño,Aleix Prat,Noemi Reguart,Amparo Benito,Pilar Garrido,Isabel Barragan,Isabel Barragan,Jean-François Emile,Rafael Rosell,Elisabeth Brambilla,Manel Esteller +48 more
TL;DR: The epigenetic milieu of NSCLC tumours indicates which patients are most likely to benefit from nivolumab or pembrolizumab treatments, and the methylation status of FOXP1 could be associated with validated predictive biomarkers such as PD-L1 staining and mutational load to better select patients who will experience clinical benefit with PD-1 blockade.